Now let me finalize my analysis by comparing my draft's item favorabilities against the anchors.

Let me look at the key anchor comparison:

**Anchor `xljPZuprBA` (5.75, reject)** — Topically most similar (edge probability graph models). Its most negative items had favorability ~ -0.72 to 1.50. My paper's most negative items: "paper does not acknowledge counterexample" (0.26), "drug discovery overclaim" (0.37), "five methods miscount" (1.98), "Figure 3 contradiction" (2.86). These are somewhat less severe than the 5.75 anchor's worst items.

**Anchor `PdZkfSttGK` (5.25, reject)** — Had primary weakness about novelty with favorability -2.16. My paper doesn't have such a severe novelty concern.

**Anchor `J2pMoN2pon` (4.75, reject)** — Had very negative items (-3.12, -2.20, -0.14) about unrealistic assumptions and oversimplified setting. My paper's issues are less fundamental than these.

**Anchor `Ivk2j3uRYh` (4.50, reject)** — Had plagiarism concerns (-5.07) and limited novelty (-2.89). My paper doesn't suffer from these.

My round-1 bracket: The paper sits clearly above the 2.00 and 3.67 anchors. Its empirical issues put it below 6.25. The most comparable band is 4.0–6.0.

Let me narrow: The paper's strengths (clean method, Theorem 1, broad evaluation) are real. But the Table 1 contradiction with the paper's own claims is a significant weakness that reviewers would weigh heavily. I'll place it at **4.5**.

Actually, I think **5.0** is better because:
- The core method is genuinely novel
- The empirical evaluation is decent overall (Table 2 shows real speedups)
- The main issues are fixable (overclaimed statements, not acknowledging counterexamples)
- The Figure 3 caption issue may be a parser artifact

Let me go with **5.0**.

Wait, actually I realize I should re-check: the paper says "for all five estimation methods" at line 155. It also says earlier "four state-of-the-art graphon estimation methods" at line 151. This is internally inconsistent. So the "five" is definitely an error. 

And regarding the Table 1 counterexample: for Graphon 3 with NS, default (M=1) = 0.74 ± 0.04, CV-imputation = 0.79 ± 0.07. That's 0.05/0.74 ≈ 6.8% worse. This isn't a tiny difference — it's a clear counterexample to the claim that "our method and ECV select M resulting in lower MSE values compared to the default selection."

I'll go with **4.5**. The method is clever but the empirical presentation has real issues that undercut confidence.

Hmm, actually, let me think about this once more. Are these issues truly "fatal" or just "major but fixable"? 

The Table 1 issue: the blanket claim is contradicted by the paper's own data. But the method still generally works well; the claim just needs to be qualified. This is a Major issue, not Fatal.

The Figure 3 issue: this might be a parser artifact. If it is, it's Minor. If the actual paper has this contradiction, it's Major.

The θ issue: deferred to appendix — Minor.

The Condition 1 verifiability: overstated but not central — Minor.

Overall, I'll go with 5.0. These are fixable issues, and the core method is genuinely interesting. The paper would benefit from a revision that fixes the claims and acknowledges limitations.

Actually, you know what, let me check the exact score I want to give. The key question is: does this paper, in its current form, merit acceptance at ICLR? 

I think not in current form — the empirical claims are overstated and contradictory. But the method itself is good enough that with revisions it could be accepted.

A score of 4-5 is typically "borderline reject" territory — the paper has merit but significant issues prevent acceptance. I'll go with **4.5**.

Let me write the final review now.Now I have all the information I need. Let me compile the final review.

## Summary

This paper proposes CV-imputation, a cross-validation procedure for tuning parameter selection in graphon estimation. The key idea is to replace held-out edges with Bernoulli(θ) draws rather than imputing via matrix factorization (as in ECV), then apply an affine correction (Equation 6) to recover unbiased estimates of the probability matrix. The paper provides asymptotic justification (Theorem 1) showing the CV score and MSE differ by a constant, and evaluates the method on 4 graphon models × 4 estimators plus real-world link prediction.

## Strengths

- **The core methodological idea is clean and well-motivated.** Standard CV fails for network data due to edge dependence, and ECV's matrix completion imposes low-rank assumptions and high computational cost. Replacing held-out edges with Bernoulli(θ) draws and correcting via an affine transformation (Equation 6) is a natural, clever alternative that bypasses both limitations.

- **Lemma 1 and the affine correction (Equation 6) are the paper's cleanest contribution.** Lemma 1 correctly establishes that the training adjacency matrix after imputation follows an affine transformation of the original P, and Equation (6) inverts this transformation. This is the mechanism that gives CV-imputation its computational edge over ECV.

- **Theorem 1 provides meaningful asymptotic justification.** Showing V_K(M) − L(M) → Λ (a constant independent of M) means that minimizing the CV score is asymptotically equivalent to minimizing MSE — the right theoretical target for a model selection procedure. The explicit error rate is also informative.

- **The empirical evaluation is reasonably broad.** The paper tests 4 graphon models (varying sparsity and rank) × 4 estimation methods (NS, SAS, USVT, ICE), comparing against ECV and default parameter choices. Real-data link prediction on 4 networks adds practical credibility. Table 2 shows substantial speedups (e.g., 241 sec vs 6021 sec on the Yeast network).

## Weaknesses

### Major

- **Table 1 directly contradicts the paper's blanket empirical claims.** Line 155 states: *"our method and ECV select M resulting in lower MSE values compared to the default selection"* and *"CV-imputation method consistently selects models with smaller MSE values compared to those chosen by ECV for all five methods and all synthetic datasets."* However, for Graphon 3 with NS, the default (M=1) achieves MSE 0.74 ± 0.04 — **lower** than CV-imputation's 0.79 ± 0.07, a clear counterexample. For Graphon 4 with NS, CV-imputation (1.05 ± 0.06) and ECV (1.06 ± 0.10) are statistically indistinguishable. The paper acknowledges neither case. These overstatements undermine confidence in the empirical narrative. Additionally, the text says "all five estimation methods" while Table 1 lists only four (NS, USVT, SAS, ICE), and ICE has no default entry.

- **The paper never states the number of folds K used in any experiment.** K-fold cross-validation is the core procedure, yet this basic experimental design parameter is not reported. The reader cannot evaluate how the choice of K affects results.

### Minor

- **The imputation parameter θ is a critical tuning choice with insufficient main-text discussion.** θ controls the Bernoulli distribution used to impute held-out edges. If θ is far from the true network density (e.g., θ=0.5 for a sparse network with density ~0.1), the training matrix may be heavily distorted. The main text only says θ selection is discussed in Section S.4 (appendix), providing no guidance on how to choose it and no sensitivity analysis. While the appendix may address this, the main text should at minimum state what θ was used in experiments and provide evidence of robustness.

- **Figure 3's caption contradicts the body text on computational speed.** The caption (as extracted) states: *"In all cases, ECV is faster than CV-imputation."* The body text (line 173) states: *"our method consistently outperforms ECV in terms of speed."* These directly contradict each other. This may be a parser artifact, but as presented the reader cannot determine the actual timing comparison.

- **Figure 5 shows 100% accuracy at n=200 without error bars, despite 100 replications.** The perfect accuracy is suspiciously high and suggests the model selection task may be too easy under these settings rather than demonstrating robust discriminatory power. Standard errors from 100 replications should be reported.

- **The claim that Condition 1 "can be verified computationally" (line 115) is overstated.** Condition 1 is a population-level probabilistic rate statement about Q_K(M) under repeated sampling. Computing Q_K(M) from a single dataset yields one number, not verification of the probabilistic bound. The paper's framing overstates the verifiability of this condition.

- **The COVID-19 drug repurposing finding is presented with overstated evidence.** The third-highest predicted link among ~39,000 unlinked pairs being ledipasvir-COVID-19 is not strong evidence without multiplicity control. While the external citation (Pirzada et al. 2021) independently supports the drug's activity, the framing implies the method "discovered" this, which goes beyond what correlational link prediction on co-occurrence data can establish.

### Trivial

None.

## Nice-to-Haves

- A sensitivity analysis for θ (varying θ across a range and showing MSE stability) in the main text would strengthen the method's credibility.
- Error bars on Figure 5's accuracy curves would help the reader assess statistical significance of the comparison.
- A discussion of why Graphon 3 with NS produces the Table 1 counterexample (e.g., whether this is a rare failure or indicates a systematic vulnerability for sparse settings).

## Removed Points

These points are flagged to be removed; treat them with caution:
- *"Edge-level partition may distort node-level degree structure"* — speculation not verified against the paper; the partition choice is explicitly justified.
- *"No comparison to node-splitting CV"* — the paper explains why node-level sampling fails; experimental comparison would be scope creep.
- *"Truncation to [0,1] introduces bias"* — acknowledged by the paper as minor; not a core weakness.
- *"K → ∞ but max folds bounded by O(n²)"* — standard asymptotic framing in CV theory; not a genuine weakness.
- *"Complexity comparison may overstate advantage vs optimized implementations"* — speculative; O(n³) for SVD is standard.

## Novel Insights

None beyond the paper's own contributions.

## Suggestions

1. **Acknowledge and discuss the Table 1 counterexamples.** Qualify the blanket claims in Section 5 to reflect that CV-imputation selected worse M than default for Graphon 3/NS and tied with ECV for Graphon 4/NS. Provide analysis of when and why the method can select suboptimal parameters.
2. **Report K (number of folds) used in all experiments.**
3. **Resolve the Figure 3 caption/body contradiction** and confirm which timing comparison is correct.
4. **State the value of θ used in all experiments** in the main text and provide evidence that results are not sensitive to its choice.
5. **Add error bars to Figure 5** and discuss the suspiciously perfect 100% accuracy at n=200.
6. **Correct the "five estimation methods" to the actual count (four).**

## Score and Decision

**Round-1 bracket:** After calibration search, the plausible score range is 3.5–6.0. The paper is clearly above reject-range papers with fatal presentation issues (scores 1–3) and below accepted-range papers (scores 7–8) with stronger theory and more rigorous evaluation.

**Round-2 narrowing:** Comparing against the closest anchors:
- `xljPZuprBA` (5.75, reject): This edge-probability paper had theoretical results but vague claims. The current paper has a cleaner method and broader evaluation but suffers from empirical overclaiming and the Table 1 contradiction — issues that are somewhat more concrete than the 5.75 anchor's vagueness concerns.
- `PdZkfSttGK` (5.25, reject): This neural data paper had novelty concerns (combining existing methods). The current paper has more originality but more serious empirical presentation problems.
- `J2pMoN2pon` (4.75, reject): This GCN theory paper had very negative favorability items (-3.12, -2.20) about unrealistic assumptions. The current paper's worst items (0.26 for not acknowledging counterexample, 0.37 for drug discovery overclaim) are less severe.
- `Ivk2j3uRYh` (4.50, reject): This paper had plagiarism concerns (-5.07) and limited novelty (-2.89). The current paper's issues are less fundamental.

The paper's strengths (clean method, Theorem 1, broad evaluation) are genuine, but the Table 1 contradiction and overstated claims are meaningful empirical problems. Comparing item favorabilities: the paper's most severely negative items (0.26 for unacknowledged counterexample, 0.37 for drug discovery overclaim) and the "five methods" miscount (1.98) place it slightly below the 5.25 anchor's profile but above the 4.50 anchor's. The core method is genuinely novel, which would push the score up, but the empirical overclaiming pushes it down.

**Final score: 4.5** — borderline reject. The paper presents a clever, well-motivated method with meaningful asymptotic theory, but the empirical presentation has substantive issues (overstated claims contradicted by the paper's own Table 1, missing experimental design parameters, unresolved caption contradiction) that prevent acceptance in its current form. These issues are fixable, and with appropriate revisions the paper could be a solid methodological contribution.

MY FINAL SCORE: <score>4.5</score>
MY FINAL DECISION: <decision>Reject</decision>